The EYA4 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population, generated from the human Raji B-lymphocyte suspension line. This product provides a heterogeneous pool of cells carrying targeted disruption of the EYA4 gene, enabling loss-of-function studies without clonal selection. It serves as a ready-to-use knockout model for investigating EYA4-dependent biological processes in a lymphoid context.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive B-lymphocyte line derived from a Burkitt’s lymphoma patient. Raji cells grow in suspension and are extensively employed as a model for B-cell immunology, signal transduction, and lymphoma biology. Their well-characterized growth properties and relevance to hematological malignancies make them a robust platform for gene-editing applications.
EYA4 encodes a dual-function protein acting as a transcriptional coactivator within the Six1-EYA4-Dach1 developmental complex and as a tyrosine phosphatase that dephosphorylates H2AX at DNA double-strand breaks, thereby promoting DNA repair. It is regulated upstream by Six1, Wnt, and TGF-?? signaling, and interacts with DNA-PKcs to modulate the DNA damage response. Downstream, the Six1-EYA4 complex transcriptionally regulates targets such as cyclin D1, while EYA4 phosphatase activity influences ??H2AX foci resolution. EYA4 also intersects with Hippo pathway components Yap1 and Taz, integrating developmental and repair signals.
In the Raji B-cell model, disruption of EYA4 is particularly relevant for dissecting the interplay between DNA damage repair, apoptosis, and lymphomagenesis. Loss of EYA4 function may impair H2AX dephosphorylation, leading to persistent DNA damage signals and altered cell cycle control, which can be assessed by ??H2AX immunofluorescence and comet assays. Given the role of EBV in B-cell transformation, this knockout system also permits examination of viral?Chost interactions in the context of genomic instability.
Typical applications include mechanistic studies of autosomal dominant sensorineural hearing loss (DFNA10) and dilated cardiomyopathy, where EYA4 mutations are pathogenic, as well as broader cancer research focusing on colorectal and gastric tumors. In the Raji background, researchers can investigate B-cell lymphoma biology, screen for therapeutic agents targeting EYA4-associated pathways, and validate drug responses using proliferation and apoptosis flow cytometry assays. The polyclonal format preserves population diversity, mitigating clone-specific artifacts. For additional details, please contact Ascent Research.
